---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-060784"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:13:57.749192+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NYSE accepts Annovis Bio's plan to regain listing compliance; 18-month cure period

## Summary
- Annovis received NYSE acceptance of its plan to regain compliance with minimum market capitalization and stockholders' equity standards.
- NYSE granted an 18-month period from March 26, 2025, to achieve compliance; stock remains listed subject to plan adherence.
- Annovis must provide quarterly progress updates to NYSE; business operations and SEC reporting unaffected.

## SEC filing metadata
- accession: 0001104659-25-060784
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/0001104659-25-060784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/tm2518347d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-060784
- JSON: https://secwatch.observer/filing/0001104659-25-060784.json
- Plain text: https://secwatch.observer/filing/0001104659-25-060784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.